.png)
.png)
.png)
OBJECTIVE: Renal transplantation (RTx) is the best therapeutic modality for end-stage renal disease
patients. We report 8 years single-centre experience on cadaveric and living donor RTx in terms of
demographic features along with graft functions, posttransplant medical complications, patients-graft
survivals.
MATERIAL and METHODS: We enrolled 66 RTx (female/male: 36/30) patients including 40
cadaveric and 26 living donors. At admission age, gender, causes of renal failure, dialysis typeduration, type of RTx, induction and maintenance immunosuppressive modalities, rejection episodes,
biochemistry-hemogram parameters at 1, 6, 12, 24 and 60 months after transplantation and medical
complications were obtained from the medical records.
RESULTS: Mean recipient age was 41±11.6 years. Mean transplant duration was 32.2±31.4 months,
and the mean creatinine values was 1.4±0.9 mg/dl. The most commonly used immunosuppressive
protocol was corticosteroid+tacrolimus+mycophenolate mofetil. Delayed graft function, chronic
allograft nephropathy and acute rejection were observed in 27.3%, 25.7% and 13.6% of patients,
respectively. 1- and 5-year patient survival rates were 100% and 100% for living donor patients and 85% and 85% for cadaveric patients, respectively. 1- and 5-year graft survival rates were 100% and 100% for living donor RTx patients, and 80%
and 80% for cadaveric RTx patients, respectively. The most common medical complications were new onset diabetes mellitus and dyslipidemia.
The most common early and late infection was urinary tract infection.
CONCLUSION: RTx is the best renal replacement therapy in terms of patient-graft survival. However, patients should be closely moniterized for
metabolic complications.